Irritable bowel syndrome cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Cost-effectiveness of therapy
Cost-effectiveness of therapy
- The aggregate cost of IBS in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.[1]
- A 49% annual increase in medical costs is associated with a diagnosis of IBS.[2][3]
- IBS patients have average annual direct costs of $5,049 and $406 in out-of-pocket expenses.[4]
- IBS patients have a reported 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.[5]
- IBS patients have high costs for physician visits, outpatients visits, and prescription drugs.
- In 2007, IBS was associated with an increase of $962 in Medicaid costs in California, and $2191 in North Carolina.
- Cost of IBS is comparable to asthma patients.[6]
Research spending on IBS
Research spending on IBS
- The National Institutes of Health provides a searchable database for grant awards since 1974 on its CRISP database, and provides dollar amounts for recent awards on its Intramural Grant Award Page.
- In 2006, the NIH awarded approximately 56 grants related to IBS, amounting to approximately $18,787,710.
References
References
- ↑ Hulisz D. (2004). “The burden of illness of irritable bowel syndrome: current challenges and hope for the future”. J Manag Care Pharm. 10 (4): 299–309. PMID 15298528.
- ↑ Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. (2001). “Costs of care for irritable bowel syndrome patients in a health maintenance organization”. Am J Gastroenterol. 96 (11): 3122–9. PMID 11721759.
- ↑ Leong SA, Barghout V, Birnbaum HG; et al. (2003). “The economic consequences of irritable bowel syndrome: a US employer perspective”. Arch. Intern. Med. 163 (8): 929–35. doi:10.1001/archinte.163.8.929. PMID 12719202.
- ↑ “Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain”. Aliment Pharmacol Ther. 26 (2): 237–48. 2007. PMID 17593069. Text ” author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. ” ignored (help)
- ↑ Paré P, Gray J, Lam S; et al. (2006). “Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study”. Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
- ↑ Martin B, Ganguly R, Pannicker S, Feride F;Barghout V (2003). “Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome”. Curr Med Res Opin. 19 (8): 771–780. PMID 12719202.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH